GlaxoSmithKline (GSK) at ASHG 2026

Oct 20–24, 2026 Montréal, Canada ~7.5k attendees Website

GlaxoSmithKline (GSK) at ASHG 2026 in Montréal: 1 presentation (1 featured symposium).

Organization	ASHG 2026 Attendance
GlaxoSmithKline (GSK) Collegeville, Pennsylvania	1 Senior Director, Translational Genetics and Phenomics
gsk.com\|LinkedIn Public company~66,800 people GSK prevents and treats disease with specialty medicines, vaccines and general medicines for patients worldwide. GSK completed its acquisition of Nuvalent, adding three lung-cancer assets to its oncology portfolio. › GSK completed its acquisition of Nuvalent, adding three lung-cancer assets to its oncology portfolio. 2026-07 · source GSK completed its acquisition of 35Pharma, adding HS235, a potential best-in-class pulmonary hypertension molecule. 2026-04 · source GSK completed its acquisition of RAPT, adding ozureprubart, a long-acting anti-IgE monoclonal antibody. 2026-03 · source Source: company newsroom Q2 2026 sales £8.4B, up 5% › FY2026 guidance reaffirmed at 3%-5% turnover growth and 7%-9% core operating profit growth. · 2026-07-28 “Total Q2 sales £8.4 billion +5% AER; +5% CER. / 2026 guidance reaffirmed with expected growth in: turnover 3% to 5%; Core OP 7% to 9%; Core EPS 7% to 9%.” Source: results release	Symposium Wed Oct 21 9:05 am Part of The All of Us Research Program At 10 Years: 500,000+ Genomes Advancing Precision Medicine Contextualizing and integrating All of Us with other global biobank data in drug discovery Room 517BC/Level 5

Organization

ASHG 2026 Attendance

GlaxoSmithKline (GSK)

Collegeville, Pennsylvania

1 Senior Director, Translational Genetics and Phenomics

gsk.com|LinkedIn

Public company~66,800 people

GSK prevents and treats disease with specialty medicines, vaccines and general medicines for patients worldwide.

GSK completed its acquisition of Nuvalent, adding three lung-cancer assets to its oncology portfolio.

›

GSK completed its acquisition of Nuvalent, adding three lung-cancer assets to its oncology portfolio.

2026-07 · source

GSK completed its acquisition of 35Pharma, adding HS235, a potential best-in-class pulmonary hypertension molecule.

2026-04 · source

GSK completed its acquisition of RAPT, adding ozureprubart, a long-acting anti-IgE monoclonal antibody.

2026-03 · source

Source: company newsroom

Q2 2026 sales £8.4B, up 5%

›

FY2026 guidance reaffirmed at 3%-5% turnover growth and 7%-9% core operating profit growth. · 2026-07-28

“Total Q2 sales £8.4 billion +5% AER; +5% CER. / 2026 guidance reaffirmed with expected growth in: turnover 3% to 5%; Core OP 7% to 9%; Core EPS 7% to 9%.”

Source: results release

Symposium

Wed Oct 21
9:05 am

Part of The All of Us Research Program At 10 Years: 500,000+ Genomes Advancing Precision Medicine

Contextualizing and integrating All of Us with other global biobank data in drug discovery

Room 517BC/Level 5

Instantly find 20 buyers from GlaxoSmithKline (GSK)

Get a list of who you should contact, their contact info, and what to say.

Totally free and instant, no sign up necessary!

Not affiliated with or endorsed by the American Society of Human Genetics. Submit a correction